Celgene will use adenoviral siRNA and cDNA libraries across its research programmes to study key disease pathways and identify novel drug targets
Celgene, a biopharmaceutical company with focus on the discovery, development and commercialisation of innovative therapies for unmet medical needs in cancer and inflammatory disease, and Galapagos, a target discovery and adenoviral services company, have entered into a multi-year target discovery collaboration. Galadeno (Galapagos's wholly owned services unit) will provide Celgene with its adenoviral siRNA and cDNA libraries, SilenceSelect and FlexSelect.
These libraries enable the knock-down or over-expression of the human drugable genome in human primary cell assays.
Celgene will use these libraries across Celgene's research programmes to study key disease pathways and identify novel drug targets.
"Galadeno is unique in the siRNA field right now, due to its in depth experience of not only providing tools, but also applying them in complex biological assays", said Celgene's CSO, David Stirling.
"This expertise, combined with their robust technology platform gives us confidence regarding the discovery prospects for this collaboration.
"We are delighted to be working with Celgene which is one of the most exciting biopharmaceutical companies in their field," said Onno van de Stolpe, CEO of Galapagos.
"We are also very pleased that Celgene has joined the growing number of companies that have chosen to use our adenoviral siRNA and gene expression technologies to drive their target and drug discovery effort."
